ReviewF1000Research2019
The nocebo effect as a source of bias in the assessment of treatment effects.
Review in F1000Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- What patient reported outcome measures are used in clinical trials in hip fracture? A systematic mapping review.BMC musculoskeletal disorders · 2026Pooled it
- Nocebo effects in systemic therapies for adult plaque psoriasis: A systematic review and meta-analysis.Frontiers in medicine · 2024Pooled it
- Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients.The New England journal of medicine · 2026Trial
- Informed Consent for Placebo-Controlled Trials: Do Ethics and Science Conflict?Ethics & human research · 2022Trial
- Placebo response mitigation with a participant-focused psychoeducational procedure: a randomized, single-blind, all placebo study in major depressive and psychotic disorders.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021Trial
- The "Are You OK?" Paradox: A Scoping Review of Nocebo and Negative Suggestion in Healthcare Communication.Dentistry journal · 2026Review
- Migraine treatment with CGRP monoclonal antibodies: patient evaluation of a mandatory treatment holiday in Belgium.Acta neurologica Belgica · 2025Article
- Placebo and nocebo phenomena in schizophrenia spectrum disorders: a narrative review on current knowledge and potential future directions.Psychological medicine · 2025Review
- Patient reported pain following tooth extraction with different autologous platelet concentrates. Systematic review.BDJ open · 2025Article
- Classic Psychedelics for the Treatment of Depression: Potential Benefits and Challenges.Drugs · 2025Review
- Democratising clinical trials research to strengthen primary health care.The Lancet. Global health · 2025Review
- Negative expectations (nocebo phenomenon) in clinical interventions: A scoping review.Journal of education and health promotion · 2024Article
- Placebo: a brief updated review.Naunyn-Schmiedeberg's archives of pharmacology · 2022Review
- Patient-reported outcome measures (PROMs) as proof of treatment efficacy.BMJ evidence-based medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The term nocebo effect refers to the harmful outcomes that result from people's negative beliefs, anticipations, or experiences related to the treatment rather than the pharmacological properties of the treatment. These outcomes may include a worsening of symptoms, a lack of expected improvement, or adverse events, and they may occur after the active treatment and the placebo that is supposed to imitate it. The nocebo effect is always unwanted and may distort estimates of treatment effectiveness and safety; moreover, it may cause discontinuation of therapy or withdrawal from a trial. The nocebo effect may be unintentionally evoked by the explanations given by healthcare professionals during a clinical consultation or consent procedures, or by information from other patients, the media, or the Internet. Moreover, it may be a consequence of previous bad experiences with the treatment, through learning and conditioning, and the conditioning may happen without patients' conscious awareness. In trial settings, a study design, for example lack of blinding, may introduce bias from the nocebo effect. Unlike the placebo effect, which is usually taken into consideration while interpreting treatment outcomes and controlled for in clinical trials, the nocebo effect is under-recognised by clinical researchers and clinicians. This is worrying, because the nocebo phenomenon is common and may have potentially negative consequences for the results of clinical treatment and trials. It is therefore important that doctors and medical researchers consider any potential nocebo effect while assessing the treatment effect and try to minimise it through careful choice and phrasing of treatment-related information given to patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.